研究

Fujino Y, Nagai Y.

The molecular pathogenesis of repeat expansion diseases.

Kusunoki S.

CSF sphingomyelin: possible biomarker of demylination.

Kusunoki S, Willison HJ, Jacobs BC.

Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective.

Inada R, Miyamoto K, Tanaka N, Moriguchi K, Kadomatsu K, Takeuchi K, Igarashi M, Kusunoki S.

Chondroitin sulfate N-acetylgalactosyltransferase-1 knockout shows milder phenotype in experimental autoimmune encephalomyelitis than in wild type.

Yoon BA, Ha DH, Park HT, Kusunoki S, Kuwahara M, Lee JH, Bae JS, Kim JK.

Finger drop sign as a new variant of acute motor axonal neuropathy.

Watanabe M, Nakamura Y, Sato S, Niino M, Fukaura H, Tanaka M, Ochi H, Kanda T, Takeshita Y, Yokota T, Nishida Y, Matsui M, Nagayama S, Kusunoki S, Miyamoto K, Mizuno M, Kawachi I, Saji E, Ohashi T, Shimohama S, Hisahara S, Nishiyama K, Iizuka T, Nakatsuji Y, Okuno T, Ochi K, Suzumura A, Yamamoto K, Kawano Y, Tsuji S, Hirata M, Sakate R, Kimura T, Shimizu Y, Nagaishi A, Okada K, Hayashi F, Sakoda A, Masaki K, Shinoda K, Isobe N, Matsushita T, Kira JI.

HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.

Moriguchi K, Miyamoto K, Fukumoto Y, Kusunoki S.

Change in light-dark cycle affects experimental autoimmune encephalomyelitis.

Inada R, Hirano M, Oka N, Samukawa M, Saigoh K, Suzuki H, Udaka F, Hashiguchi A, Takashima H, Hamada Y, Nakamura Y, Kusunoki S.

Phenotypic and molecular diversities of spinocerebellar ataxia type 2 in Japan.

Verboon C, Harbo T, Cornblath DR, Hughes RAC, van Doorn PA, Lunn MP, Gorson KC, Barroso F, Kuwabara S, Galassi G, Lehmann HC, Kusunoki S, Reisin RC, Binda D, Cavaletti G, Jacobs BC.

IGOS consortium. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.

Ikeda Y, Mitsui Y, Kaji H, Isogai N, Akagi M, Matsumura I.

Characteristics of Medical Students who Repeated the Same Grade Using the DREEM Questionnaire.

Jiang S, Baba K, Okuno T, Kinoshita M, Choong C.J, Hayakawa H, Sakiyama H, Ikenaka K, Nagano S, Sasaki T, Shimamura M, Nagai Y, Hagihara K, Mochizuki H.

Go-sha-jinki-Gan alleviates inflammation in neurological disorders via p38-TNF signaling in the central nervous system.

Choong C.J., Okuno T., Ikenaka K., Baba K., Hayakawa H., Koike M., Yokota M., Doi J., Kakuda K., Takeuchi T., Kuma A., Nakamura S., Nagai Y., Nagano S., Yoshimori T., Mochizuki H.

Alternative mitochondrial quality control mediated by extracellular release.

Shibata T, Nagano K, Ueyama M, Ninomiya K, Hirose T, Nagai Y, Ishikawa K, Kawai G, Nakatani K.

Small molecule targeting r(UGGAA)n disrupts RNA foci and alleviates disease phenotype in Drosophila model.

Hervás R., Fernández-Ramírez M.D.C, Galera-Prat A, Suzuki M, Nagai Y, Bruix M, Menéndez M., Laurents D.V, Carrión-Vázquez M.

Divergent CPEB prion-like domains reveal different assembly mechanisms for a generic amyloid-like fold.

Oura S, Noda T, Morimura N, Hitoshi S, Nishimasu H, Nagai Y, Nureki O, Ikawa M.

Precise CAG repeat contraction in a Huntington’s Disease mouse model is enabled by gene editing with SpCas9-NG.

Ohnari K, Okada K, Mafune K, Kusunoki S, Adachi H.

Unclassified subtype of Guillain-Barré syndrome is associated with quick recovery.

Ishikura T, Kinoshita M, Shimizu M, Yasumizu Y, Motooka D, Okuzaki D, Yamashita K, Murata H, Beppu S, Koda T, Tada S, Shiraishi N, Sugiyama Y, Miyamoto K, Kusunoki S, Sugimoto T, Kumanogoh A, Okuno T, Mochizuki H.

Anti-AQP4 autoantibodies promote ATP release from astrocytes and induce mechanical pain in rats.

Porto KJ, Hirano M, Mitsui J, Chikada A, Matsukawa T, Ishiura H; Japan Multiple System Atrophy Registry Consortium, Toda T, Kusunoki S, Tsuji S.

COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population.

Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, Attarian S, Benedetti L, Briani C, Casasnovas C, Castellani F, Dardiotis E, Echaniz-Laguna A, Garssen MPJ, Harbo T, Huizinga R, Humm AM, Jellema K, van der Kooi AJ, Kuitwaard K, Kuntzer T, Kusunoki S, Lascano AM, Martinez-Hernandez E, Rinaldi S, Samijn JPA, Scheidegger O, Tsouni P, Vicino A, Visser LH, Walgaard C, Wang Y, Wirtz PW, Ripellino P, Jacobs BC;

IGOS consortium. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study.

Mori K., Gotoh S., Yamashita T., Uozumi R., Kawabe Y., Tagami S., Kamp F., Nuscher B., Edbauer D., Haass C., Nagai Y., Ikeda M.

TMPyP4 inhibits elongation during the non-canonical translation of the GGGGCC repeat in C9orf72 FTLD/ALS.

Ishiguro A., Lu J., Ozawa D., Nagai Y., Ishihama A.

ALS-linked FUS mutations dysregulate G-quadruplex-dependent liquid-liquid phase separation and liquid-to-solid ttansition.

Minakawa E.N, Nagai Y.

Protein aggregation inhibitors as disease-modifying therapies for polyglutamine diseases.

Ishiguro T, Nagai Y. Ishikawa K.

Insight into spinocerebellar ataxia type 31 (SCA31) from Drosophila model.

Kusunoki S, Willison HJ, Jacobs BC.

Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective.

Nagai Y.

Arginine as a disease-modifying therapeutic candidate for the polyglutamine diseases by stabilizing polyglutamine protein conformation and inhibiting its aggregation.

小澤大作，永井義隆．

相分離現象を通して見る神経変性疾患

永井義隆

神経変性疾患克服への展望

田港朝也, 永井義隆.

脆弱X関連振戦/失調症候群(FXTAS).

桑原基, 楠　進.

自律神経障害を伴うGuillain-Barré症候群と自己抗体.

窪田愛恵, 三井良之, 池田行宏, 伊木雅之, 平出敦

近畿大学医学部の学生における留年等に関する決定木分析
-IRとしての分析-

寒川真

重症筋無力症における補体標的薬の適応と効果

桑原基

免疫チェックポイント阻害薬による神経系有害事象

寒川真, 楠　進

糖尿病性ニューロパチーとの鑑別を要した高齢発症抗NF155抗体陽性CIDP